What the studies show
Raises IGF-1 as intended; small rises in blood glucose and injection-site reactions are documented. Long-term cancer risk at elevated IGF-1 is the reason for the narrow label.
Several well-run randomised trials in people, pointing the same way. You can plan around this. It still says nothing about whether the effect is worth the side effects for you.
- 1Falutz J, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: pooled analysis of two phase 3 trials.J Acquir Immune Defic Syndr, 2010;53:311–322816 participants; the approval basis.
In context
Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone, approved in the United States to reduce excess abdominal fat in people with HIV-associated lipodystrophy. In that population it cuts visceral fat by about 15% over six months, and the fat returns when treatment stops. Its use for general fat loss, muscle or anti-ageing rests on extrapolation from that specific group; there are no trials in healthy adults. It is not authorised in the EU.
Tesamorelin is approved (rx, us). Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is Tesamorelin proven to cause IGF-1 elevation and glucose effects?
What studies are behind the grade?
Is Tesamorelin approved for this?
Other outcomes for Tesamorelin
- AVisceral fat (HIV lipodystrophy)2 phase 3 RCTs (n=816)
- BLiver fat (HIV with NAFLD)1 RCT (n=61)
- CCognition in older adults1 RCT (n=152)
- DFat loss in healthy adultsNone
Reviewed 2 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →